

**Monash Centre of Cardiovascular Research
& Education in Therapeutics**

State of the Art in
Cardiovascular Therapeutics:
**ANTI-PLATELET
THERAPY**

12.15-1.15pm FRIDAY 8th of August, 2008
Glenroy Room, Mercure Grosvenor Hotel, Adelaide



 **MONASH** University

ABSTRACT BOOK

**This symposium is supported by an unrestricted educational
grant from Bristol-Myers Squibb**

 **MONASH** University



PROGRAM

Chairs:

Prof HENRY KRUM & A/Prof ANDREW AJANI

12.15 pm – Dr STEPHEN DUFFY
Anti-platelet therapy following PCI

12.30 pm – Prof BARRY MASSIE
Anti-platelet therapy in Heart Failure

12.45 pm – Prof DEREK CHEW
Anti-platelet therapy in ACS

1.00 pm – A/Prof ANDREW AJANI
Where are we now with APT therapy?

Thanks To

We wish to thank Bristol-Myers Squibb for supporting this symposium program.





The Monash Centre of Cardiovascular Research and Education in Therapeutics (**CCRE Therapeutics**) had its genesis as a NHMRC Centre for Clinical Research Excellence in 2002. The centre was established within the Department of Epidemiology & Preventive Medicine at Monash University under the direction of Professors Henry Krum, John McNeil, Andrew Tonkin, Andrew Forbes, Paul Myles and Flavia Cicuttini.

The aim of CCRE Therapeutics is to improve clinical outcomes at the individual and community level through the use of evidence, based upon high quality clinical research. Reflecting the diverse range of expertise of its faculty, CCRE's activities span from bench to bedside. The core strengths can be divided into three main areas; Clinical Trials, Clinical Informatics and Pharmacoepidemiology/ Translational Research. CCRE's Education programs aim to facilitate the dissemination of the latest clinical research to enhance evidence-based cardiovascular clinical practice.

Further information is available on our website;
www.ccretherapeutics.org.au



Associate Professor Andrew Ajani is Director of Coronary Care at the Royal Melbourne Hospital.

A/Prof Ajani's research interests lie in interventional cardiology and he is convener of the Melbourne Interventional Group (MIG), who have established a large multi-centre registry of coronary interventional procedures capturing procedural data and long-term outcomes in Victorian patients across seven public hospitals.



Barry M. Massie, MD is a Professor of Medicine at the University of California in San Francisco and Chief of the Cardiology Division at the San Francisco VAMC. He is a nationally and internationally recognized researcher and clinician in the fields of heart failure and hypertension.

Dr. Massie was the Principal Investigator of the Warfarin and Antiplatelet Trial in Chronic Heart Failure (WATCH), a multi-centre, multi-national trial being conducted under the auspices of the VA Cooperative Study Program. He is also the Co-Principal Investigator of the ongoing I-PRESERVE trial, the largest study of the treatment of patients with heart failure and preserved ejection

What's New in Anti-platelet Management for ACS?

Professor Derek Chew

Clinical trial evidence supporting the importance of anti-platelet therapy for acute coronary syndromes is now extensive, with data supporting the use of these therapies extending from the management of acute ST-segment elevation myocardial infarction, non-ST segment elevation acute coronary syndromes and percutaneous coronary intervention. Recommendations of their use are now well supported by robust internationally supported clinical guidelines. However, despite this evidence, several challenges remain including: the need to optimize dosing to provide the greatest ischemic benefit while limiting bleeding risk; attaining therapeutic levels rapidly within the context of time critical care; the potential need for individualization of therapy among those patients with reduced anti-platelet therapy responsiveness; and more complete application of these proven therapies among under served patient groups. This presentation will explore these issues in greater detail.



Dr Stephen Duffy is Head of Cardiology General Services at the Alfred Hospital, and Head of the Coronary Pathophysiology Laboratory at the Baker IDI Heart and Diabetes Institute.

His research interests include vulnerable plaque and what makes certain individuals vulnerable to acute coronary syndromes, along with coronary intervention outcomes research. He is a founding member of the Melbourne Interventional Group (MIG), which is a large multi-centre registry of coronary intervention procedures in Victoria, Australia. He is a local Principal Investigator on a number of trials of anti-platelet therapy, and has been a Principal Investigator on several first-in-man cardiovascular device trials.



Professor Derek Chew is the Acting Director of Cardiovascular Medicine at the Flinders Medical Centre and the Roy and Marjorie Edwards Professor of Cardiovascular Outcomes Research at Flinders University. After undertaking a two-year interventional cardiology fellowship at the Cleveland Clinic Foundation, he moved on to the Harvard School of Public Health, completing a Masters of Public Health in Quantitative Methods. Professor Chew is the author of numerous manuscripts and book chapters in the field of general and intervention cardiology, and has been involved with the design of several clinical trials. He has a particular interest in clinical trial design, risk stratification and cardiovascular outcomes research.

